EUVIMEDEUVIMED entdecken
Crossref

Clinical Characteristics of Pathogenic ACAN Variants and 3-Year Response to Growth Hormone Treatment: Real-World Data

Judith S Renes, Ardine M J Reedijk, Monique Losekoot, Sarina G Kant, Manouk Van der Steen, Danielle C M Van der Kaay, Anita C S Hokken-Koelega, Hermine A Van Duyvenvoorde, Christiaan de Bruin

Hormone Research in Paediatrics · 2024

DOI: 10.1159/000535651 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hormone Research in Paediatrics, 2024. Verfasst von Judith S Renes und 8 weiteren Autor:innen. Beteiligte Einrichtung: Dutch Growth Research Foundation, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Aggrecans, Human Growth Hormone. Die Arbeit wurde bisher 14-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Heterozygous variants in the ACAN gene may underlie disproportionate short stature with characteristically accelerated bone age (BA) maturation and/or early-onset osteoarthritis (OA).

Methods

The objective of this study was to describe phenotype, analyze genotype-phenotype correlations, and assess the response of growth hormone (GH) treatment in children with a heterozygous ACAN variant. Thirty-six subjects (23 boys, 13 girls) with ACAN deficiency and treated for ≥1 year with GH were identified in the Dutch National Registry of GH treatment in children.

Results

We identified 25 different heterozygous ACAN variants in 36 subjects. Median (interquartile range) height SDS at start of GH was −2.6 SDS (−3.2 to −2.2). Characteristic features such as disproportion, advanced BA, early-onset OA, and dysmorphic features like midface hypoplasia and brachydactyly were present in the majority of children, but in ∼20%, no specific features were reported. Subjects with a truncating ACAN variant had a shorter height SDS compared to subjects with a non-truncating variant (−2.8 SDS and −2.1 SDS, respectively, p = 0.002). After 3 years of GH, height gain SDS in prepubertal children was 1.0 SDS (0.9–1.4). In pubertal children, height SDS remained relatively stable.

Conclusion

The phenotype of subjects with pathogenic heterozygous ACAN variants is highly variable, and genetic testing for ACAN deficiency should be considered in any child with significant short stature, even in the absence of disproportion, specific dysmorphic features, or BA advancement. Furthermore, children with ACAN deficiency may benefit from GH with a modest but significant response, which is sustained during 3 years of treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AggrecansHuman Growth HormoneHumansMaleFemaleChildChild, PreschoolAdolescentBody HeightPhenotype

Stichwörter der Autor:innen

ACANAggrecanGrowth hormoneTreatment response

Substanzen

ACAN protein, humanAggrecansHuman Growth Hormone

Autor:innen und Institutionen

  • Dutch Growth Research Foundation, Rotterdam, The Netherlands.
  • Department of Pediatrics, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
  • Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Department of Pediatric Endocrinology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Pediatrics, Subdivision of Endocrinology, Erasmus University Medical Center, Sophia Children's Hospital, Rotterdam, The Netherlands.

Zitieren

APA

Renes, J. S., Reedijk, A. M. J., Losekoot, M., Kant, S. G., Van der Steen, M., Van der Kaay, D. C. M., Hokken-Koelega, A. C. S., Van Duyvenvoorde, H. A., & de Bruin, C. (2024). Clinical Characteristics of Pathogenic ACAN Variants and 3-Year Response to Growth Hormone Treatment: Real-World Data. Hormone Research in Paediatrics. https://doi.org/10.1159/000535651

Vancouver

Renes JS, Reedijk AMJ, Losekoot M, Kant SG, Van der Steen M, Van der Kaay DCM, et al. Clinical Characteristics of Pathogenic ACAN Variants and 3-Year Response to Growth Hormone Treatment: Real-World Data. Hormone Research in Paediatrics. 2024. doi:10.1159/000535651

BibTeX
@article{Renes2024,
  author = {Renes, Judith S and Reedijk, Ardine M J and Losekoot, Monique and Kant, Sarina G and Van der Steen, Manouk and Van der Kaay, Danielle C M and Hokken-Koelega, Anita C S and Van Duyvenvoorde, Hermine A and de Bruin, Christiaan},
  title = {Clinical Characteristics of Pathogenic ACAN Variants and 3-Year Response to Growth Hormone Treatment: Real-World Data},
  journal = {Hormone Research in Paediatrics},
  year = {2024},
  doi = {10.1159/000535651}
}
Kostenlos starten →